News

TASTE: Thrombus aspiration has no mortality benefit in STEMI


 

FROM THE ESC CONGRESS 2013

"Today it may be possible to design and conduct megatrials with what we have: bigger data and smaller budgets," they wrote. "Yet we must also recognize and acknowledge the daunting challenges that diverse groups of researchers and stakeholders must overcome to get there."

TASTE was funded by the Swedish Research Council and Swedish Association of Local Authorities and Regions. Dr. Fröbert also reported unrestricted grants from Terumo, Medtronic, and Vascular Solutions, and consultancy for Stentys and Biotronik. His coauthors reported financial ties with numerous research and commercial entities. Dr. Lauer, Dr. D’Agostino, and Dr. Byrne reported having no relevant financial conflicts. Dr. Kastrati reported receiving fees from Biotronik, the Medicines, Astra-Zeneca, MSD, St. Jude Medical, and Biosensors.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

TRILOGY: Prasugrel, Clopidogrel Look Similar in ACS Patients
MDedge Emergency Medicine
ED troponin testing called big time saver
MDedge Emergency Medicine
Progress, obstacles cited in building STEMI networks
MDedge Emergency Medicine
Is same-day discharge after PCI safe?
MDedge Emergency Medicine
One-year outcomes support emergency department CCTA
MDedge Emergency Medicine
STREAM trial endorses fibrinolysis-first in selected STEMIs
MDedge Emergency Medicine
High-sensitivity troponin T assay shows prognostic superiority
MDedge Emergency Medicine
Swedish NSTEMI registry suggests comparability of heparin, bivalirudin
MDedge Emergency Medicine
Vitamin C protects kidneys against angiography contrast
MDedge Emergency Medicine